Literature DB >> 2050679

On the mechanism of fibrin-specific plasminogen activation by staphylokinase.

H R Lijnen1, B Van Hoef, F De Cock, K Okada, S Ueshima, O Matsuo, D Collen.   

Abstract

The mechanism of plasminogen activation by recombinant staphylokinase was studied both in the absence and in the presence of fibrin, in purified systems, and in human plasma. Staphylokinase, like streptokinase, forms a stoichiometric complex with plasminogen that activates plasminogen following Michaelis-Menten kinetics with Km = 7.0 microM and k2 = 1.5 s-1. In purified systems, alpha 2-antiplasmin inhibits the plasminogen-staphylokinase complex with k1(app) = 2.7 +/- 0.30 x 10(6) M-1 s-1 (mean +/- S.D., n = 12), but not the plasminogen-streptokinase complex. Addition of 6-aminohexanoic acid induces a concentration-dependent reduction of k1(app) to 2.0 +/- 0.17 x 10(4) M-1 s-1 (mean +/- S.D., n = 5) at concentrations greater than or equal to 30 mM, with a 50% reduction at a 6-aminohexanoic acid concentration of 60 microM. Staphylokinase does not bind to fibrin, and fibrin stimulates the initial rate of plasminogen activation by staphylokinase only 4-fold. Staphylokinase induces a dose-dependent lysis of a 0.12-ml 125I-fibrin-labeled human plasma clot submersed in 0.5 ml of citrated human plasma; 50% lysis in 2 h is obtained with 17 nM staphylokinase and is associated with only 5% plasma fibrinogen degradation. Corresponding values for streptokinase are 68 nM and more than 90% fibrinogen degradation. In the absence of a fibrin clot, 50% fibrinogen degradation in human plasma in 2 h requires 790 nM staphylokinase, but only 4.4 nM streptokinase. These results suggest the following mechanism for relatively fibrin-specific clot lysis with staphylokinase in a plasma milieu. In plasma in the absence of fibrin, the plasminogen-staphylokinase complex is rapidly neutralized by alpha 2-antiplasmin, thus preventing systemic plasminogen activation. In the presence of fibrin, the lysine-binding sites of the plasminogen-staphylokinase complex are occupied and inhibition by alpha 2-antiplasmin is retarded, thus allowing preferential plasminogen activation at the fibrin surface.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2050679

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

Review 1.  Thrombolytic therapy in acute myocardial infarction.

Authors:  U Priglinger; K Huber
Journal:  Drugs Aging       Date:  2000-04       Impact factor: 3.923

Review 2.  Advances in thrombolytic therapy.

Authors:  M Verstraete
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

Review 3.  Streptokinase--the drug of choice for thrombolytic therapy.

Authors:  Adinarayana Kunamneni; Thaer Taleb Abed Abdelghani; Poluri Ellaiah
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

4.  NMR secondary structure of the plasminogen activator protein staphylokinase.

Authors:  O Ohlenschläger; R Ramachandran; J Flemming; K H Gührs; B Schlott; L R Brown
Journal:  J Biomol NMR       Date:  1997-04       Impact factor: 2.835

5.  Full time course kinetics of the streptokinase-plasminogen activation pathway.

Authors:  Miranda Nolan; Samantha D Bouldin; Paul E Bock
Journal:  J Biol Chem       Date:  2013-08-22       Impact factor: 5.157

6.  Modification of the hemagglutinin cleavage site allows indirect activation of avian influenza virus H9N2 by bacterial staphylokinase.

Authors:  Longping V Tse; Gary R Whittaker
Journal:  Virology       Date:  2015-04-01       Impact factor: 3.616

7.  The evolution of recombinant thrombolytics: Current status and future directions.

Authors:  Yogender Pal Khasa
Journal:  Bioengineered       Date:  2016-10-03       Impact factor: 3.269

8.  Fibrin-targeted plasminogen activation by plasminogen activator, PadA, from Streptococcus dysgalactiae.

Authors:  Satish Singh; Timsy Bhando; Kanak L Dikshit
Journal:  Protein Sci       Date:  2014-04-05       Impact factor: 6.725

9.  Purification and biochemical characterization of a 17 kDa fibrinolytic enzyme from Schizophyllum commune.

Authors:  In Suk Park; Jeong Uck Park; Min Jeong Seo; Min Jeong Kim; Hye Hyeon Lee; Sung Ryeal Kim; Byoung Won Kang; Yung Hyun Choi; Woo Hong Joo; Yong Kee Jeong
Journal:  J Microbiol       Date:  2011-01-09       Impact factor: 3.422

10.  Temperature-sensitive liposome-mediated delivery of thrombolytic agents.

Authors:  Vishal Saxena; Carmen Gacchina Johnson; Ayele H Negussie; Karun V Sharma; Matthew R Dreher; Bradford J Wood
Journal:  Int J Hyperthermia       Date:  2015-03-13       Impact factor: 3.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.